Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by New Mexico Educational Retirement Board

New Mexico Educational Retirement Board lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 5,100 shares of the biopharmaceutical company’s stock after selling 100 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Regeneron Pharmaceuticals were worth $3,633,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Trust Co. of Vermont lifted its holdings in Regeneron Pharmaceuticals by 8.3% in the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 12 shares during the period. Nvwm LLC increased its position in Regeneron Pharmaceuticals by 1.4% during the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after purchasing an additional 14 shares in the last quarter. Moss Adams Wealth Advisors LLC increased its position in Regeneron Pharmaceuticals by 3.6% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock worth $456,000 after purchasing an additional 15 shares in the last quarter. Westhampton Capital LLC increased its position in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Westhampton Capital LLC now owns 893 shares of the biopharmaceutical company’s stock worth $939,000 after purchasing an additional 15 shares in the last quarter. Finally, Howe & Rusling Inc. boosted its stake in Regeneron Pharmaceuticals by 3.4% in the 3rd quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $486,000 after buying an additional 15 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $673.60 on Friday. The stock has a market cap of $74.02 billion, a P/E ratio of 17.60, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. The company has a current ratio of 4.73, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average of $706.92 and a 200-day moving average of $897.42. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $11.86 EPS. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of research analyst reports. Evercore ISI decreased their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. Robert W. Baird reduced their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 5th. Finally, Piper Sandler reduced their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.